Certain drugs [e.g., anti-VEGFR2 monoclonal antibody (Li et al. 2006), sunitinib (Ozao-Choy et al. 2009)] destroy tumor blood vessels and trigger immune response by increasing the levels of CD4+ and CD8+ T lymphocytes, as well as by inhibiting the activity of immunosuppressive Treg or myeloid-derived suppressor cells (MDSC) (Szala et al. 2010). Here, CD4 is linked to neoplasm.